



ASSURING THE SAFETY, QUALITY AND EFFICACY  
OF VETERINARY MEDICINES

United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
KT15 3LS  
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT

Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats

**PuAR correct as of 16/04/2018 when RMS was transferred  
to IE. Please contact the RMS for future updates.**

## **MODULE 1**

### **PRODUCT SUMMARY**

EU Procedure number	UK/V/0245/001/DC
Name, strength and pharmaceutical form	Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
Applicant	Animalcare Limited
Active substance	Buprenorphine hydrochloride
ATC Vetcode	QN02AE01
Target species	Dogs and Cats
Indication for use	Post-operative analgesia in the cat and dog. Potentiation of the sedative effects of centrally acting agents in the dog.

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies (veterinary) (HMA(v)) website ([www.hma.eu](http://www.hma.eu)).

## **MODULE 3**

### **PUBLIC ASSESSMENT REPORT**

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	27 February 2008
Date product first authorised in the Reference Member State (MRP only)	n/a
Concerned Member States for original procedure	Austria Belgium France Germany Ireland Luxembourg Netherlands Spain

#### **I. SCIENTIFIC OVERVIEW**

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

## II. QUALITY ASPECTS

### **A. Composition**

The product contains buprenorphine hydrochloride and excipients glucose anhydrous, hydrochloric acid water for Injections.

The container/closure system comprises type I glass ampoules, five of which are contained within a cardboard carton. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### **B. Method of Preparation of the Product**

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### **C. Control of Starting Materials**

The active substance is buprenorphine hydrochloride, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are three excipients for this product and these are anhydrous glucose, hydrochloric acid and water for injections. Each is well known in veterinary medicines and is controlled against the relevant Ph. Eur. monograph.

### **D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### **E. Control on intermediate products**

There are no intermediate products.

### **F. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

#### **G. Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

#### **H. Genetically Modified Organisms**

Not applicable to this product.

#### **J. Other Information**

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

The product does not contain an antimicrobial preservative. Advice is given to use immediately after opening the ampoule. Any solution remaining in an ampoule following withdrawal of the required dose should be discarded.

Special precautions for storage

Do not store above 25°C.

Protect from light.

Do not refrigerate or freeze

### **III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)**

#### **III.A Safety Testing**

##### **Pharmacological Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product is/are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment.

### ***Toxicological Studies***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product is/are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment.

### ***User Safety***

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

### ***Ecotoxicity***

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

## **IV CLINICAL ASSESSMENT (EFFICACY)**

### ***IV.A Pre-Clinical Studies***

#### ***Pharmacology***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

#### ***Tolerance in the Target Species of Animals***

The application is made in accordance with Article 13 (1) of Directive 2001/82/EC as amended by Directive 2004/28/EC, on the basis of being a generic of a reference medicinal product, no further information is required as it has already been presented for the reference product. Bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.

### ***IV.B Clinical Studies***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

## **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile

for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.



## **MODULE 4**

### **POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)